Pfizer Licenses Valentis GeneSwitch System | GenomeWeb

NEW YORK, Oct. 25 – Pfizer licensed Valentis’ GeneSwitch gene regulation technology, the companies announced on Wednesday.

The license is non-exclusive for research-use only.

Financial details of the agreement were not disclosed.

Burlingame, Calif.-based Valentis’ GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, according to the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."